scholarly journals Complications, long-term outcome and quality of life following Surgisis® and muscle-covered implants in immediate breast reconstruction: a case-control study with a 6-year follow-up

2018 ◽  
Vol 42 (1) ◽  
pp. 33-42 ◽  
Author(s):  
Håkan Hallberg ◽  
Richard Lewin ◽  
Madiha Bhatti Søfteland ◽  
Emmelie Widmark-Jensen ◽  
Ulrika Kogler ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Case Control Study ◽  
Case Control ◽  
Immediate Breast Reconstruction ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Control Study

scholarly journals Long-term outcome and quality of life after CNS cavernoma resection: eloquent vs. non-eloquent areas

2021 ◽  
Author(s):  
Loay Shoubash ◽  
Jörg Baldauf ◽  
Marc Matthes ◽  
Michael Kirsch ◽  
Matthias Rath ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Short Form ◽  
Preoperative Evaluation ◽  
Patient Counseling ◽  
Surgical Morbidity ◽  
Term Outcome ◽  
Long Term Outcome

AbstractThe aim of this study is to analyze the long-term quality of life after surgery of cavernoma. A monocentric retrospective study was conducted on 69 patients with cavernoma treated microsurgically between 2000 and 2016. The eloquence was adopted from Spetzler-Martin definition. A most recent follow-up was elicited between 2017 and 2019, in which the quality of life (QoL) was evaluated with the Short Form-12 questionnaire (SF12). Forty-one lesions were in eloquent group (EG), 22 in non-eloquent group (NEG), 3 in orbit, and 3 in the spinal cord. Postoperative worsening of the modified Rankin scale (mRS) occurred in 19.5% of cases in EG versus 4.5% in NEG. After a mean follow-up of 6.5 years (SD 4.6), the neurological status was better or unchanged compared to baseline in 85.4% of EG and 100% of NEG. Regarding QoL assessment of 44 patients (EG n = 27, NEG n = 14) attended the last follow-up. Patients after eloquent cavernoma resection reported a non-inferior QoL in most SF12 domains (except for physical role) compared to NEG. However, they reported general health perception inferior to norms, which was affected by the limited physical and emotional roles. At a late follow-up, the surgical morbidity was transient in the NEG and mostly recovered in the EG. The QoL comparison between eloquent and non-eloquent cavernomas created interesting and new data after prolonged follow-up. These results add value for decision-making as well as patient counseling for future encountered cases. Preoperative evaluation of QoL is recommended for future studies to assess QoL dynamics.

scholarly journals Long-term outcome and prognostic factors in enthesitis-related arthritis: A case–control study

2006 ◽  
Vol 54 (11) ◽  
pp. 3573-3582 ◽  
Author(s):  
Berit Flatø ◽  
Anna-Maria Hoffmann-Vold ◽  
Andreas Reiff ◽  
ØYstein Førre ◽  
Gunnhild Lien ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Case Control Study ◽  
Case Control ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Enthesitis Related Arthritis ◽  
Control Study

Long-term outcome of kidney transplantation in patients with a urinary conduit: a case–control study

2013 ◽  
Vol 45 (2) ◽  
pp. 405-411 ◽  
Author(s):  
Inez K. B. Slagt ◽  
Jan N. M. IJzermans ◽  
Mustafa Alamyar ◽  
Paul C. M. S. Verhagen ◽  
Willem Weimar ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Case Control Study ◽  
Case Control ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Control Study

Long-Term Outcome after Dynamic Graciloplasty for Treatment of Persistent Fecal Incontinence in Patients with Anorectal Malformations

2018 ◽  
Vol 29 (03) ◽  
pp. 276-281
Author(s):  
Johan Danielson ◽  
Urban Karlbom ◽  
Tomas Wester ◽  
Wilhelm Graf
Keyword(s):  
Quality Of Life ◽  
Fecal Incontinence ◽  
Short Form ◽  
Anorectal Malformations ◽  
Dynamic Graciloplasty ◽  
Term Outcome ◽  
Long Term Outcome

Purpose Dynamic graciloplasty (DGP) has been used to treat severe fecal incontinence since the 1980s. Previous studies have shown an inferior outcome in patients with anorectal malformations (ARMs). Our experience has been that DGP has been appreciated by ARM -patients. The objective of the study was to evaluate the long-term outcome of DGP in our patients with ARM compared with patients with other underlying conditions. Materials and Methods Twenty-three patients operated with DGP at our institution from 1996 to 2010 were sent validated bowel function and quality of life questionnaires. Eighteen of 23 responded. Seven had ARM and 11 had other etiologies of fecal incontinence. The mean follow-up time was 11.6 years (range, 5–17). Results Four of 7 of the patients with ARM and 8 of 11 of patients with other etiologies used their implants at follow-up. The Miller incontinence score was slightly higher for patients with ARMs, but they had less constipation and higher Fecal Incontinence Quality of Life (FIQL)- and 36-Item Short Form Health Survey (SF-36) scores. None of the differences were statistically significant. Conclusion This study cannot confirm earlier reports in which DGP has an inferior outcome in patients with ARM. We therefore believe that the procedure should remain a treatment option for selected patients.

scholarly journals Long-term impact of intrauterine fetal death on quality of life and depression: a case–control study

2012 ◽  
Vol 12 (1) ◽  
Author(s):  
Ida Kathrine Gravensteen ◽  
Linda Bjørk Helgadottir ◽  
Eva-Marie Jacobsen ◽  
Per Morten Sandset ◽  
Øivind Ekeberg
Keyword(s):  
Quality Of Life ◽  
Fetal Death ◽  
Case Control Study ◽  
Case Control ◽  
Intrauterine Fetal Death ◽  
Long Term Impact ◽  
Control Study

scholarly journals AMEND study protocol: a case–control study to assess the long-term impact of invasive meningococcal disease in Australian adolescents and young adults

BMJ Open ◽  
2019 ◽  
Vol 9 (12) ◽  
pp. e032583
Author(s):  
Helen Marshall ◽  
Mark McMillan ◽  
Bing Wang ◽  
Robert Booy ◽  
Hossein Afzali ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Young Adults ◽  
Outcome Measures ◽  
Meningococcal Disease ◽  
Case Control Study ◽  
Case Control ◽  
Invasive Meningococcal Disease ◽  
Control Study

IntroductionInvasive meningococcal disease (IMD) primarily causes disease in young children and adolescents and can cause long-term disability. Many countries are considering implementation of meningococcal B and/or meningococcal ACWY vaccines to control meningococcal disease. Estimating the cost-effectiveness of meningococcal vaccine programme is hampered due to a lack of good quality costing and burden of disease data. This study aims to address this evidence gap by assessing the clinical, physical, neurocognitive, economic and societal impact of IMD on adolescents and young adults.Methods and analysisA case–control study of 64 participants with confirmed IMD (15–24 years 11 months at time of disease) and 64 control participants (17–34 years 11 months) will be conducted in Australia from 2016 to 2020. All participants will undergo a neurocognitive assessment, full medical examination, pure tone audiometry assessment and complete quality of life and behavioural questionnaires. Meningococcal cases will be assessed 2–10 years posthospitalisation and a subset of cases will be interviewed to explore in depth their experiences of IMD and its impact on their life. Primary outcome measures include general intellectual functioning from the Wechsler Adult Intelligence Scale and overall quality of life from the Health Utilities Index. Secondary outcome measures include academic achievement, executive functioning, behaviour, hearing, psychological and physical functioning. Outcome measures will be compared between cases and controls using independent t-tests or ORs, or if any significant confounders are identified, adjusted analyses (analysis of covariance or adjusted ORs) will be conducted. Thematic analysis will be used to analyse transcribed interviews and a costing model will be used to project lifetime costs.Ethics and disseminationThe Adolescent MENingococcal Disease (AMEND) study has been approved by the Human Research Ethics Committee of the Women’s and Children’s Health Network (HREC/14/WCHN/024). The results will be disseminated via peer-reviewed publications, conference presentations, study participants, and meningococcal and meningitis foundations.Trial registration numberNCT03798574.

Sign in / Sign up

Export Citation Format

Share Document